Companies sponsors |
GlaxoSmithKline (belantamab mafodotin) |
Others |
Department of Health and Social Care |
|
NHS England |
Patient carer groups |
African Caribbean Leukaemia Trust |
|
Anthony Nolan |
|
Black Health Agency for Equality |
|
Blood Cancer UK |
|
Cancer Black Care |
|
Cancer Equality |
|
Cancer52 |
|
DKMS |
|
Helen Rollason Cancer Charity |
|
Independent Cancer Patients Voice |
|
Kevin Karawa Leukaemia Trust |
|
Leukaemia Cancer Society |
|
Leukaemia Care |
|
Leukaemia UK |
|
Macmillan Cancer Support |
|
Maggie’s Centres |
|
Marie Curie |
|
Myeloma UK |
|
South Asian Health Foundation |
|
Specialised Healthcare Alliance |
|
Tenovus Cancer Care |
Professional groups |
Association of Cancer Physicians |
|
British Blood Transfusion Society |
|
British Committee for Standards in Haematology |
|
British Geriatrics Society |
|
British Institute of Radiology |
|
British Oncology Pharmacy Association |
|
British Psychosocial Oncology Society |
|
British Society for Haematology |
|
British Society of Interventional Radiology |
|
British Transplantation Society |
|
Cancer Research UK |
|
NHS Blood and Transplant |
|
Royal College of General Practitioners |
|
Royal College of Nursing |
|
Royal College of Pathologists |
|
Royal College of Physicians |
|
Royal College of Radiologists |
|
Royal Pharmaceutical Society |
|
Royal Society of Medicine |
|
Society and College of Radiographers |
|
UK Clinical Pharmacy Association |
|
UK Myeloma Forum |
|
UK Myeloma Society |
|
UK Oncology Nursing Society |
Assessment group |
Liverpool Reviews and Implementation Group |
Associated public health groups |
Public Health Wales |
|
UK Health Security Agency |
Comparator companies |
AbbVie (dexamethasone) |
|
ADVANZ Pharma (dexamethasone |
|
Amgen (carfilzomib) |
|
AS Kalceks (dexamethasone) |
|
Aspen (dexamethasone) |
|
Aspire Pharma (bortezomib, dexamethasone) |
|
Aurobindo Pharma (bortezomib) |
|
Bausch & Lomb UK (dexamethasone) |
|
Bristol Myers Squibb Pharmaceuticals (pomalidomide) |
|
Dr. Reddy's Laboratories UK (bortezomib) |
|
Glenmark Pharmaceuticals Europe (dexamethasone) |
|
Hameln pharma (dexamethasone) |
|
Hospira UK (dexamethasone) |
|
Janssen-Cilag (bortezomib, daratumumab, teclistamab) |
|
Krka UK (dexamethasone) |
|
Martindale Pharma, an Ethypharm Group Company (dexamethasone) |
|
Medac GmbH (bortezomib) |
|
Menarini Stemline UK (selinexor) |
|
MSN Laboratories Europe (bortezomib) |
|
Mylan (bortezomib) |
|
Novartis Pharmaceuticals UK (dexamethasone) |
|
Panpharma UK (dexamethasone) |
|
ParaPharm Development (dexamethasone) |
|
Pfizer (bortezomib, elranatamab) |
|
Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib) |
|
Rayner Pharmaceuticals (dexamethasone) |
|
Rosemont Pharmaceuticals (dexamethasone) |
|
Sandoz (bortezomib) |
|
Sanofi (dexamethasone, isatuximab) |
|
Santen UK (dexamethasone) |
|
Synchrony Pharma (dexamethasone) |
|
Teva UK (dexamethasone) |
|
Thame Laboratories (dexamethasone) |
|
Thea Pharmaceuticals (dexamethasone) |
|
Thornton & Ross (bortezomib) |
|
Tillomed Laboratories (bortezomib) |
|
Wockhardt UK (dexamethasone) |
|
ZR Pharma & GmBH (panobinostat) |
General commentators |
All Wales Therapeutics and Toxicology Centre |
|
Allied Health Professionals Federation |
|
Board of Community Health Councils in Wales |
|
British National Formulary |
|
Care Quality Commission |
|
Department of Health, Social Services and Public Safety for Northern Ireland |
|
Healthcare Improvement Scotland |
|
Medicines and Healthcare products Regulatory Agency |
|
National Association of Primary Care |
|
National Pharmacy Association |
|
NHS Confederation |
|
Scottish Medicines Consortium |
|
Welsh Government |
|
Welsh Health Specialised Services Committee |
Relevant research groups |
Genomics England |
|
Institute of Cancer Research |
|
Leukaemia Busters |
|
Leukaemia UK |
|
MRC Clinical Trials Unit |
|
National Institute for Health Research |